加载中
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
前收盘价
US$3.91
−US$0.01 · -0.26%
盘中时间采用ET。市场数据可能有所延迟。
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
日内区间
当前US$3.91
52周区间
当前US$3.91
盘中时间采用ET。市场数据可能有所延迟。
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
日内区间
当前US$3.91
52周区间
当前US$3.91
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 14.79万 USD | 8.26万 USD | 1.55万 USD | 1.51万 USD | 1.56万 USD |
| 毛利 | −14.79万 USD | −8.26万 USD | −1.55万 USD | −1.51万 USD | −1.56万 USD |
| 研究与开发 | 2950.18万 USD | 2718.81万 USD | 2048.25万 USD | 1028.74万 USD | 252.56万 USD |
| 销售、一般及管理费用 | 808.26万 USD | 615.46万 USD | 1059.82万 USD | 932.03万 USD | 619.28万 USD |
| 营业费用 | 3758.44万 USD | 3334.27万 USD | 3108.07万 USD | 1960.77万 USD | 871.52万 USD |
| 利息收入 | 16.64万 USD | 28.36万 USD | 119.7万 USD | 17.39万 USD | 4017 USD |
| 利息支出 | 5.13万 USD | — | — | 1244 USD | 10.02万 USD |
| 折旧和摊销 | 10.73万 USD | 8.39万 USD | 1.53万 USD | 1.53万 USD | 1.53万 USD |
| 营业利润 | −3773.23万 USD | −3334.27万 USD | −3108.07万 USD | −1960.77万 USD | −871.52万 USD |
| 净利润 | −3649.38万 USD | −479.33万 USD | −2711.44万 USD | −3442.02万 USD | −1726.7万 USD |
公司数据更新于 2026年10月11日。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
